TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06616168
Drug: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
Study: NCT05015335
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10mg qw
Study: NCT04736108
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg oral low dose prednisone, once daily
Study: NCT05470933
Drug: WJ01075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.
Study: NCT05131477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06415214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05125562
Drug: ExoFlo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
Study: NCT04845620
Drug: ARQ-151 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 Cream - Vehicle
Study: NCT06139055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching-placebo oral tablets.
Study: NCT06139055
Drug: Placebo (Capsule/Tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching-placebo oral capsules or tablets.
Study: NCT05339646
Drug: SSD8432 dose 8~9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
Study: NCT05122221
Drug: Fludarabine + Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
Study: NCT05420779
Drug: Investigator's choice of chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
Study: NCT06293326
Drug: bi-layer calcium carbonate tablet (BAY1180654)
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study: NCT06293326
Drug: Immediate release calcium carbonate tablet (BAY1180654)
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study: NCT05762484
Drug: Clindamycin 1 % Topical Lotion
Normalized name: clindamycin 1 % Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% lotion if needed
Study: NCT05392374
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 is an oral, small molecule selective antagonist of DRD2
Study: NCT04669717
Drug: 1/d 500 mg Azithromycine Pfizer for 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Study: NCT05947370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT05685277
Drug: Tritace® Plus tablet 10 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
Study: NCT05387148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
Study: NCT05889234
Drug: Conventional pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
Study: NCT05265819
Drug: thyroid hormone replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: thyroid hormone replacement therapy
Study: NCT05266079
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
Study: NCT05266079
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er-Xian decoction
Study: NCT04094948
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose-filled capsules
Study: NCT04774341
Drug: anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
Study: NCT04754334
Drug: ORMD-0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Insulin
Study: NCT05369078
Drug: THR-1442 20mg Multiple dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: THR-1442 20mg is administrated QD for 7days, then follow till day 14.
Study: NCT06504147
Drug: Radspherin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
Study: NCT06148545
Drug: Elemental iron
Normalized name: Elemental Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
Study: NCT06148545
Drug: Elemental iron and Vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
Study: NCT05354089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM on day 0 and day 21.
Study: NCT04681651
Drug: Normobaric Hyperoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
Study: NCT00320567
Drug: norgestimate/ethinyl estradiol
Normalized name: Norgestimate/Ethinyl Estradiol 28-Day 0.215mg-0.025mg/0.25mg-0.025mg/0.18mg-0.025mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04711967
Drug: drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT02575508
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05774756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Study: NCT06557356
Drug: LY3532226
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06557356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04997395
Drug: MediCabilis Cannabis sativa 50
Normalized name: CANNABIS SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Already described
Study: NCT04677855
Drug: PCUR-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsules
Study: NCT05947812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
Study: NCT05641051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases will receive the same volume of IV placebo / 6 hours.
Study: NCT05545111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching NBI-1117568
Study: NCT05101369
Drug: INCB086550
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
Study: NCT05724446
Drug: Prednisolone acetate ophthalmic suspension, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfine sterile ophthalmic suspension of dense and whitish appearance.
Study: NCT06031129
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline contain 0.9% NaCl sodium.
Study: NCT05470764
Drug: TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
Study: NCT05919381
Drug: Gentuximab Injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study: NCT04791566
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
Study: NCT04878614
Drug: Levothyroxine Tablet
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard clinical management
Study: NCT04878614
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liquid levothyroxine through enteral feeding tube
Study: NCT05009732
Drug: GT0918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg once daily orally
Study: NCT05009732
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard of care per written policies or guidelines
Study: NCT05009732
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06663189
Drug: treatment withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will STOP their DMT
Study: NCT04700280
Drug: GLPG3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 film-coated tablet.
Study: NCT04700280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablet.
Study: NCT05477160
Drug: STAR-0215 (SC)
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-0215 will be administered as an SC bolus injection.
Study: NCT05477160
Drug: Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an SC bolus injection.
Study: NCT05477160
Drug: STAR-0215 (IV)
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-0215 will be administered as an IV bolus injection.
Study: NCT05477160
Drug: Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an IV bolus injection.
Study: NCT05009836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
Study: NCT06126965
Drug: KX-826-（5%） BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
Study: NCT04932941
Drug: MP1032
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules for oral administration.
Study: NCT04932941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matched to MP1032 for oral administration.
Study: NCT05109650
Drug: BAT6026
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions
Study: NCT05109650
Drug: BAT1308
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ⅳ infusions
Study: NCT05753670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
Study: NCT04333472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally every 12 hours for up to 28 days
Study: NCT06482671
Drug: Rikkunshi-to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
Study: NCT04761705
Drug: JV-GL1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Treatment
Study: NCT06665165
Drug: AMX0114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
Study: NCT05748119
Drug: MEB-1170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study: NCT05748119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent number and size of capsules containing placebo
Study: NCT05787002
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
Study: NCT04940949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - powder for solution for infusion
Study: NCT06616207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
Study: NCT05914545
Drug: FZ-AD004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles.
Study: NCT05733624
Drug: SCAI-001 0.01% eyedrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 12weeks
Study: NCT05733624
Drug: SCAI-001 0.02% eyedrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 12weeks
Study: NCT05733624
Drug: Restasis 0.05% eyedrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 12weeks
Study: NCT05841147
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of normal saline
Study: NCT06666322
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum
Study: NCT06666322
Drug: Sfu-AM2-19 Injection - antifungal therapy 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
Study: NCT05785689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus saline
Study: NCT06666322
Drug: Antifungal therapy 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be determined
Study: NCT04158349
Drug: mFOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
Study: NCT05486104
Drug: Hemay005 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
Study: NCT05486104
Drug: Hemay005 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 placebo tablets will be orally administered twice daily.
Study: NCT05450328
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions.
Study: NCT04737343
Drug: Azathioprine Tablets
Normalized name: Azathioprine Tablets
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
Study: NCT05364931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously once daily
Study: NCT05070702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard Capsule
Study: NCT06409650
Drug: KX-826 dosed at 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
Study: NCT06409650
Drug: KX-826 dosed at 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Study: NCT06409650
Drug: Matching placebo to KX-826
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically to scalp once daily for 24 weeks
Study: NCT06409650
Drug: Matching placebo to KX-826
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically to scalp twice daily for 24 weeks
Study: NCT05023577
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g bid
Study: NCT04601038
Drug: CORT108297
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
Study: NCT04601038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken as 2 tablets daily for 2 weeks
Study: NCT05380323
Drug: LY3541105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05380323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05877079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
Study: NCT05964790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
Study: NCT05472818
Drug: [11C]APP311
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
Study: NCT04715763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules filled with an inactive ingredient